We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
21hon MSN
Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy doubled in the fourth quarter, but the Danish ...
Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback